Drug Profile
Colykade
Latest Information Update: 16 Dec 2003
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer ML Laboratories
- Class
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 16 Dec 2003 Discontinued - Phase-II for Pain in United Kingdom (unspecified route)
- 12 Feb 2001 A full scale phase III development programme is currently in preparation
- 22 Nov 1999 Phase-II clinical trials for Pain in United Kingdom (Unknown route)